-+ 0.00%
-+ 0.00%
-+ 0.00%

NanoViricides wins DRC approval for Phase II trial of NV-387 oral gummies for Ebola treatment

PUBT·08/10/2026 12:31:25
Listen to the news
NanoViricides wins DRC approval for Phase II trial of NV-387 oral gummies for Ebola treatment
  • NanoViricides won ACOREP clearance in DR Congo to launch a Phase II trial of NV-387 oral gummies for Bundibugyo ebolavirus.
  • Om Sai Clinical Research was hired as CRO; drug supply for trial start is already in-country.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608100830ACCESSWRNAPR_____1205313) on August 10, 2026, and is solely responsible for the information contained therein.